logo
Plus   Neg
Share
Email

Kenmare Resources Says Achieved Or Exceeded Midpoint Of Finished Products Guidance Ranges

Kenmare Resources plc. (KMR.L), in its trading update for the fourth quarter and the full year ended 31 December 2020, said that it achieved or exceeded the midpoint of its August 2020 guidance ranges for all finished products. It targets an uplift of ilmenite production in 2021 of between approximately 45% and 60%. In addition to higher revenues, increased production will deliver lower unit costs.

In the fourth-quarter 2020, Kenmare produced 219,100 tonnes of ilmenite, a 7% increase from last year.

Total shipments of finished products in fiscal year 2020 were 853,100 tonnes, a 17% decrease from the prior year, impacted by adverse weather conditions during a significant portion of the year and reduced availability of the transhipment vessels, which underwent works to increase capacity. Shipments were comprised of 766,500 tonnes of ilmenite, 43,100 tonnes of primary zircon, 6,300 tonnes of rutile and 37,200 tonnes of concentrates.

The company expects production of all finished products for fiscal year 2021 to be higher than in fiscal year 2020, due primarily to WCP B mining higher grade ore in Pilivili. Ilmenite production in 2021 is expected to be 1.1 million to 1.2 million tonnes, building towards 1.2 million tonnes per annum on a consistent basis.
QKenmare will release its 2020 Preliminary Results on Wednesday 24 March 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT